Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
ANG Lifesciences India's Total Liabilities for the quarter that ended in Mar. 2026 was ₹1,560.6 Mil.
ANG Lifesciences India's quarterly Total Liabilities
declined
from Sep. 2025 (₹1,842.57 Mil) to Dec. 2025 (₹0.00 Mil) but then
increased
from Dec. 2025 (₹0.00 Mil) to Mar. 2026 (₹1,560.59 Mil).
ANG Lifesciences India's annual Total Liabilities
declined
from Mar. 2024 (₹1,661.60 Mil) to Mar. 2025 (₹1,656.18 Mil) and
declined
from Mar. 2025 (₹1,656.18 Mil) to Mar. 2026 (₹1,560.59 Mil).
ANG Lifesciences India Total Liabilities Related Terms
ANG Lifesciences India Total Liabilities Historical Data
* Premium members only.
The historical data trend for ANG Lifesciences India's Total Liabilities can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ANG Lifesciences India Total Liabilities Calculation
Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.
ANG Lifesciences India's Total Liabilities for the fiscal year that ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
What does a Total Liabilities of ₹1,560.6 Mil mean?
ANG Lifesciences India (BOM:540694) has a Total Liabilities of ₹1,560.6 Mil as of Mar. 2026. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ANG Lifesciences India and its competitors.
Is ANG Lifesciences India's Total Liabilities too high?
ANG Lifesciences India's current Total Liabilities is ₹1,560.6 Mil. Overall, ANG Lifesciences India has a GF Score™ of 62/100 and is considered Modestly Overvalued, reflecting its overall financial health beyond just this single metric.
How does ANG Lifesciences India's Total Liabilities compare to ZTS and UTHR?
ANG Lifesciences India's Total Liabilities of ₹1,560.6 Mil can be compared against companies in the Drug Manufacturers industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Liabilities for a Drug Manufacturers company?
A good Total Liabilities depends on the Drug Manufacturers industry context. However, Total Liabilities should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Liabilities mean?
A high Total Liabilities can signal that a stock is expensive relative to its fundamentals. The total amount of liabilities as recorded on a company's balance sheet. View historical data for ANG Lifesciences India and its competitors. ANG Lifesciences India's current Total Liabilities is ₹1,560.6 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is ANG Lifesciences India stock overvalued right now?
Based on GuruFocus' analysis, ANG Lifesciences India (BOM:540694) is currently considered Modestly Overvalued. The stock's GF Value™ is ₹30.51, compared to a current price of ₹36.43 — trading 19.4% above its estimated fair value. The current Total Liabilities is ₹1,560.6 Mil. ANG Lifesciences India's overall GF Score™ is 62/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Liabilities calculated?
Total Liabilities is calculated from a company's financial statements. For ANG Lifesciences India (BOM:540694), the current Total Liabilities is ₹1,560.6 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is ANG Lifesciences India (BOM:540694) Overvalued in 2026?
Based on GuruFocus' analysis, ANG Lifesciences India stock appears to be overvalued.
The current stock price of ₹36.43 is trading 19.4% above its estimated GF Value™ of ₹30.51.
GuruFocus considers ANG Lifesciences India to be Modestly Overvalued.
Key valuation signals for BOM:540694:
Total Liabilities: ₹1,560.6 Mil
GF Value™: ₹30.51 vs. price of ₹36.43 (19.4% above fair value)
No single metric tells the full story. See the BOM:540694 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
ANG Lifesciences India Ltd is engaged in the business of manufacturing and sales of finished pharmaceutical formulations in a dosage form of sterile dry powder injection vials, liquid injection vials, ampoules, PFS, hard gelatin capsules, soft gelatin capsules, dry syrups, liquid syrups and suspension, lotions, etc. Its product portfolio comprises various therapeutic categories such as antibiotics, antivirals, antimalarial, antiulcer, carbapenem, corticosteroid, penicillin, beta-lactamase inhibitor, etc. Through its subsidiary, it is also involved in the business of printing and packing solutions. The group's reportable segments are Pharmaceuticals, which derive maximum revenue, and Packaging and printing. Geographically, it derives maximum revenue from India.
62GF Score
Get the complete analysis for BOM:540694
Total Liabilities is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
BOM:540694 has been successfully added to your 
